• Medicine
• Published in
  Expert opinion on emerging…
  2015
• DOI:10.1517/14728214.2015.1018177

Emerging drugs for secondary hyperparathyroidism.

@article{Cozzolino2015EmergingDF,
  title={Emerging drugs for secondary hyperparathyroidism.},
  author={Mario Cozzolino and James R. Tomlinson and Liron Walsh and Antonio Bellasi},
  journal={Expert opinion on emerging drugs},
  year={2015},
  volume={20 2},
  pages={
          197-208
        }
}

• Mario Cozzolino, James R. Tomlinson, +1 author Antonio Bellasi

INTRODUCTION Secondary hyperparathyroidism (SHPT), a common, serious, and progressive complication of chronic kidney disease (CKD), is characterized by elevated serum parathyroid hormone (PTH), parathyroid gland hyperplasia, and mineral metabolism abnormalities. These disturbances may result in CKD-mineral and bone disorder (CKD-MBD), which is associated with poor quality of life and short life expectancy. AREAS COVERED The goal of SHPT treatment is to maintain PTH, calcium, and phosphorus… CONTINUE READING

View on PubMed

Alternate Sources

Save to Library

Create Alert

Cite